Chloral Hydrate

Summary

Chloral Hydrate (CHEMBL455917) is an approved small-molecule general anaesthetic (ATC N05CC01); indicated across 5 conditions including anxiety and brain disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CC01
• Indications: 5 conditions
• Chemistry: 165.4 Da · C2H3Cl3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL455917
Name	Chloral Hydrate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2707
ChEBI	CHEBI:28142
ATC	N05CC01
Molecular formula	C2H3Cl3O2
Molecular weight	165.4
InChIKey	RNFNDJAIBTYOQL-UHFFFAOYSA-N

SMILES: C(C(Cl)(Cl)Cl)(O)O

IUPAC name: 2,2,2-trichloroethane-1,1-diol

ChEBI definition: An organochlorine compound that is the hydrate of trichloroacetaldehyde.

Pharmacological roles (ChEBI): sedative, general anaesthetic.

Other ChEBI roles (chemical / environmental): xenobiotic, mouse metabolite.

Also known as: Chloral hydrate, Chlorali hydras, Chloralum, Cloral hydrate, Noctec, NSC-3210, Chloral Hydrate, SID29215298, SID144205167, SID170465484, SID144207308, CHLORAL HYDRATE

Patent coverage: 16,704 distinct patent families (34,297 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
brain disorder	3	MONDO:0005560	EFO:0005774
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).